Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997691

SCHEMBL21997691

SCHEMBL21997691

CNc1c(N)cccc1OCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ APP P05067 2/20 0.49
▸ LTA4H P09960 1/20 0.49
▸ MAPK14 Q16539 1/20 0.49
▸ LIPE Q05469 1/20 0.46
▸ DCPS Q96C86 1/20 0.44
▸ NUDT1 P36639 1/20 0.44
▸ HTR1A P08908 6/20 0.44
▸ ADRA1D P25100 5/20 0.44
▸ ADRA1A P35348 5/20 0.44
▸ ADRA1B P35368 5/20 0.44
▸ GAA P10253 1/20 0.44
▸ BRD4 O60885 1/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ KDM1A O60341 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31276197 1.00 MAPT (0.54) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL15871989 0.82 MAPT (0.61) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL22369102 0.82 MAPT (0.49) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL3175163 0.81 BRD4 (0.63) MAPTMAPK1TDP1L3MBTL1GAA
SCHEMBL292275 0.79 APP (0.72) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL14200021 0.78 MAPT (0.51) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL29502858 0.78 MAPT (0.76) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL1142249 0.78 MAPT (0.76) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL3489533 0.78 MAPT (0.58) MAPTMAPK1TDP1L3MBTL1APP
SCHEMBL7018956 0.77 APP (0.56) MAPTMAPK1TDP1L3MBTL1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-12528785-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-12-26 — — US disclosed
WO-2024259303-A1 COMPOUNDS AND COMPOSITIONS AS CEREBLON LIGANDS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2024-12-19 — — WO disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11932624-B2 MDM2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-03-19 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
WO-2021188948-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 — — WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 MAPT 3470/4885MAPK1 1224/4885TDP1 2432/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885MAPK1 2017/4885TDP1 236/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885MAPK1 2017/4885TDP1 236/4885
US-20240424110-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, USP2, MYCBP2 MAPT 1541/4885MAPK1 3892/4885TDP1 1624/4885
US-12528785-B2 MDM2 degraders and uses thereof MDM2, ADRM1, RBX1 MAPT 1007/4885MAPK1 4265/4885TDP1 1935/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 MAPT 4151/4885MAPK1 1540/4885TDP1 2560/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 MAPT 2459/4885MAPK1 2017/4885TDP1 236/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885MAPK1 2017/4885TDP1 236/4885
US-11932624-B2 MDM2 degraders and uses thereof MDM2, TP53, MDM4 MAPT 1460/4885MAPK1 4323/4885TDP1 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.